Jeong GJ, et al. - In this randomized, patient/evaluator-blinded, split-face study, researchers compared the safety and effectiveness of a novel polycaprolactone (PCL)-based dermal filler, DLMR01, with that of RJR, a purified polynucleotide dermal filler. In total, 30 individuals with symmetric crow's feet of 2-4 points on the Crow's Feet Grading Scale (CFGS) were enlisted. To receive DLMR01 or RJR injections in their right or left crow's feet, each individual was randomized. Findings revealed that there was no significant difference in CFGS, Global Aesthetic Improvement Scale, and R_a value between DLMR01 side and RJR at 12 weeks (improvement rate in CFGS from baseline at week 12—DLMR01: 48.28% [14/29], RJR: 41.38% [12/29]). The novel PCL-based dermal filler DLMR01 displays suitable effectiveness and safety, widening the selection possibilities for clinicians and individuals in the treatment crow's feet.